Table III.
Efficacy results
| Parameter | DLBCL (n = 27) | FL (n = 10) | MCL (n = 18) | MZL (n = 9) | CLL/SLL (n = 17) | HL (n = 18) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Best response, n (%): | ||||||||||||
| Complete response | 12 | (44.4) | 6 | (60) | 11 | (61.1) | 8 | (88.9) | 9 | (52.9) | 7 | (38.8) |
| Partial response | 3 | (11.1) | 2 | (20) | 2 | (11.1) | 0 | (0) | 6 | (35.3) | 4 | (22.2) |
| Stable disease | 3 | (11.1) | 0 | (0) | 2 | (11.1) | 0 | (0) | 1 | (5.9) | 5 | (27.8) |
| Progressive disease | 8 | (29.6) | 2 | (20) | 2 | (11.1) | 1 | (11.1) | 0 | (0) | 1 | (5.6) |
| Unknown | 1 | (3.7) | 0 | (0) | 1 | (5.6) | 0 | (0) | 1 | (5.9) | 1 | (5.6) |
| ORR, % (95% CI) | 55.6 (35.3–74.5) | 80 (44.4–97.5) | 72.2 (46.5–90.3) | 88.9 (51.8–99.7) | 88.2 (63.6–98.5) | 61.1 (38.6–79.7) | ||||||
| Progression-free survival: | ||||||||||||
| No. of events | 13 | 7 | 8 | 2 | 5 | 9 | ||||||
| 1-year PFS, % (95% CI) | 43 (21.1–63.3) | 50 (18.4–75.3) | 63.9 (36.5–82) | 71.4 (25.8–92) | 85.7 (53.9–96.2) | 61.1 (35.3–79.2) | ||||||
| 2-year PFS, % (95% CI) | 43 (21.1–63.3) | 40 (12.3–67) | 53.3 (24.3–75.6) | 71.4 (25.8–92) | 55.1 (22–79) | 45.8 (20.9–67.8) | ||||||
| Median PFS [months] (95% CI) | 11.1 (5.5–16.7) | 8.6 (0–17.9) | 25.9 (3.1–48.6) | NE | NE | 13.2 (NE) | ||||||
| Overall survival: | ||||||||||||
| No. of events | 12 | 3 | 5 | 2 | 3 | 6 | ||||||
| 1-year OS, % (95% CI) | 48.2 (25.3–67.9) | 88.9 (43.3–98.4) | 74.9 (45.6–89.9) | 71.4 (25.8–92) | 92.9 (59.1–99) | 71.8 (47.2–87.9) | ||||||
| 2-year OS, % (95% CI) | 41.3 (25.3–67.9) | 76.2 (33.2–93.5) | 74.9 (45.6–89.9) | 71.4 (25.8–92) | 73.9 (37.9–91) | 64.6 (37–82.5) | ||||||
Note: The percentages in parentheses are column percentages. CI – confidence interval, CLL/SLL – chronic lymphocytic lymphoma/small lymphocytic lymphoma, DLBCL – diffuse large B-cell lymphoma, FL – follicular lymphoma, HL – Hodgkin lymphoma, MCL – mantle cell lymphoma, MZL – marginal zone lymphoma, NE – not estimable, ORR – objective response rate, OS – overall survival, PFS – progression-free survival.